Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC
This study aimed to explore the efficacy and biomarker explanation of IBI-323 combined with bevacizumab plus platinum based chemotherapy on ALK-rearranged non-small cell lung cancer who failed from first line Alectinib.
Non Small Cell Lung Cancer
DRUG: IBI-323 combined with bevacizumab plus Platinum
ORR, Defined as the proportion of subjects in complete remission (CR) and partial remission (PR) to the total subjects, 1 year
OS, Defined as the time from the start of treatment to the death of the subject due to any cause., 1 year|DCR, Disease control rates were assessed according to RECIST V1.1, 1 year
This study aimed to explore the efficacy and biomarker explanation of IBI-323 combined with bevacizumab plus platinum based chemotherapy on ALK-rearranged non-small cell lung cancer who failed from first line Alectinib.